Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.

Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E

International journal of obesity (2005)23 Mar 2016Cited by 398 (Europe PMC)

PMID27005405PMCIDPMC4973216DOI10.1038/ijo.2016.52PepBankPUB-27005405

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity and moderate or severe obstructive sleep apnea, liraglutide 3.0 mg reduced the apnea-hypopnea index more than placebo after 32 weeks.
In plain wordsIn adults with obesity and moderate or severe sleep apnea, liraglutide 3.0 mg reduced breathing interruptions during sleep more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseChange in apnea-hypopnea index at 32 weeks
Study
n = 359
Comparator
Placebo
Analysis
Primary
Outcome group
Sleep · Sleep
Studied dose
3.0 mg · 32 weeksAs given in this study (human).
Measurements
AHI change
−12.2 events h(-1)
liraglutide 3.0 mg
AHI change
−6.1 events h(-1)
placebo
Estimated treatment difference
−6.1 events h(-1)
liraglutide vs placebo
Source sentences
Summary
After 32 weeks, the mean reduction in AHI was greater with liraglutide than with placebo (-12.2 vs -6.1 events h(-1), estimated treatment difference: -6.1 events h(-1) (95% confidence interval (CI), -11.0 to -1.2), P=0.0150).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15-29.9 events h(-1)) or severe (AHI ⩾30 events h(-1)) OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomized for 32 weeks to liraglutide 3.0 mg (n=180) or p…
Report a problemFND-2700540501
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity and moderate or severe obstructive sleep apnea, liraglutide 3.0 mg produced greater percentage weight loss than placebo.
In plain wordsIn adults with obesity and moderate or severe sleep apnea, liraglutide 3.0 mg led to more weight loss than placebo did.
Peptide
Liraglutide
Outcome
DecreasePercentage weight loss at 32 weeks
Study
n = 359
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg · 32 weeksAs given in this study (human).
Measurements
Weight change
−5.7%
liraglutide 3.0 mg
Weight change
−1.6%
placebo
Estimated treatment difference
−4.2%
liraglutide vs placebo
Source sentences
Summary
Liraglutide produced greater mean percentage weight loss compared with placebo (-5.7% vs -1.6%, estimated treatment difference: -4.2% (95% CI, -5.2 to -3.1%), P<0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15-29.9 events h(-1)) or severe (AHI ⩾30 events h(-1)) OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomized for 32 weeks to liraglutide 3.0 mg (n=180) or p…
Report a problemFND-2700540502
03HumanRandomized controlled trialMechanism
In adults with obesity and moderate or severe obstructive sleep apnea, a post hoc analysis found a statistically significant association between the degree of weight loss and improvement in OSA end points.
In plain wordsIn adults with obesity and sleep apnea, a post hoc analysis linked more weight loss to bigger improvements in sleep apnea measures.
Peptide
Liraglutide
Outcome
Not applicableAssociation of weight loss with OSA improvement
Study
n = 359
Outcome group
Sleep · Sleep
Studied dose
3.0 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
A statistically significant association between the degree of weight loss and improvement in OSA end points (P<0.01, all) was demonstrated post hoc.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15-29.9 events h(-1)) or severe (AHI ⩾30 events h(-1)) OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomized for 32 weeks to liraglutide 3.0 mg (n=180) or p…
Report a problemFND-2700540503
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity and moderate or severe obstructive sleep apnea, liraglutide 3.0 mg reduced HbA1c more than placebo.
In plain wordsIn adults with obesity and sleep apnea, liraglutide 3.0 mg reduced HbA1c more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction
Study
n = 359
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3.0 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
Greater reductions in glycated hemoglobin (HbA1c) and systolic blood pressure (SBP) were seen with liraglutide versus placebo (both P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15-29.9 events h(-1)) or severe (AHI ⩾30 events h(-1)) OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomized for 32 weeks to liraglutide 3.0 mg (n=180) or p…
Report a problemFND-2700540504
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity and moderate or severe obstructive sleep apnea, liraglutide 3.0 mg reduced systolic blood pressure more than placebo.
In plain wordsIn adults with obesity and sleep apnea, liraglutide 3.0 mg reduced systolic blood pressure more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure reduction
Study
n = 359
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
3.0 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
Greater reductions in glycated hemoglobin (HbA1c) and systolic blood pressure (SBP) were seen with liraglutide versus placebo (both P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15-29.9 events h(-1)) or severe (AHI ⩾30 events h(-1)) OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomized for 32 weeks to liraglutide 3.0 mg (n=180) or p…
Report a problemFND-2700540505
06HumanRandomized controlled trialSafety outcome
In adults with obesity and moderate or severe obstructive sleep apnea, the safety profile of liraglutide 3.0 mg was similar to that seen with doses up to 1.8 mg.
In plain wordsIn adults with obesity and sleep apnea, the safety profile of liraglutide 3.0 mg was similar to that seen with lower doses.
Peptide
Liraglutide
Outcome
No significant changeSafety profile versus lower doses
Study
n = 359
Comparator
Liraglutide doses up to 1.8 mg (as seen before)
Outcome group
Adverse events · Metabolic and weight
Studied dose
3.0 mg · 32 weeksAs given in this study (human).
Source sentences
Summary
The safety profile of liraglutide 3.0 mg was similar to that seen with doses ⩽1.8 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, double-blind trial, non-diabetic participants with obesity who had moderate (AHI 15-29.9 events h(-1)) or severe (AHI ⩾30 events h(-1)) OSA and were unwilling/unable to use continuous positive airway pressure therapy were randomized for 32 weeks to liraglutide 3.0 mg (n=180) or p…
Report a problemFND-2700540506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03341429

Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response

University College, Londonn = 7022 Aug 2018 to 11 Jun 2020

Obesity

Trial page ClinicalTrials.govUpdated 5 Nov 2020

CompletedPhase 3Results postedNCT01557166

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Novo Nordisk A/Sn = 3597 Jun 2012 to 17 Jun 2013

Metabolism and Nutrition Disorder · Obesity · Obstructive Sleep Apnoea

Trial page ClinicalTrials.govUpdated 1 Nov 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.